Merriman Curhan Ford Initiates Coverage on Repligen (RGEN)
More News related to RGEN
- Repligen Corporation (RGEN) Narrowly Beats Estimates, Posts Q2 3c Loss
- Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Repligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST
- Repligen Announces Conference Call of Second Quarter Fiscal Year 2010 Results
Merriman Curhan Ford & Co. initiates coverage on Repligen (Nasdaq: RGEN) with a Buy rating.
To see more analyst ratings on RGEN Click Here.
Repligen Corporation (Repligen) is a biopharmaceutical company focused on the development of novel therapeutics primarily for the treatment of diseases of the central nervous system.
Related Categories
New CoverageStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
